G Mazziotti1, A M Formenti2,3, M B Panarotto3,4, E Arvat5, A Chiti6,7, A Cuocolo8, M E Dottorini9, C Durante10, L Agate11, S Filetti10, F Felicetti5, A Filice12, L Pace13, T Pellegrino14, M Rodari6, M Salvatori15, C Tranfaglia9, A Versari12, D Viola11, S Frara16, A Berruti17, A Giustina18, R Giubbini3,4. 1. Endocrine Unit, ASST Carlo Poma, Mantua, Italy. 2. Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy. 3. Nuclear Medicine, ASST Spedali Civili of Brescia, Brescia, Italy. 4. Nuclear Medicine, University of Brescia, Brescia, Italy. 5. Oncological Endocrinology, University of Turin, Torino, Italy. 6. Nuclear Medicine, Humanitas Research Hospital and Humanitas University, Milan, Italy. 7. Humanitas University, Milan, Italy. 8. Nuclear Medicine, University of Naples Federico II, Napoli, Italy. 9. Nuclear Medicine, "S. Maria della Misericordia" Hospital, Perugia, Italy. 10. Internal Medicine, University Sapienza of Rome, Roma, Italy. 11. Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. 12. Nuclear Medicine, Azienda Ospedaliera Santa Maria Nuova-IRCCS Reggio Emilia, Reggio Emilia, Italy. 13. Department of Medicine and Surgery, University of Salerno, Fisciano, Italy. 14. Institute of Biostructure and Bioimaging of the National Research Council of Italy-CNR, Naples, Italy. 15. Nuclear Medicine, Catholic University of Sacred Heart, Rome, Italy. 16. San Raffaele Vita-Salute University, Milan, Italy. 17. Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. 18. San Raffaele Vita-Salute University, Milan, Italy. giustina.andrea@hsr.it.
Abstract
PURPOSE AND PATIENTS: The M.O.S.CA.TI. (Metastases of the Skeleton from CArcinoma of the ThyroId) is a multicenter, retrospective study investigating the real-life outcome and management of bone metastases (BM) in 143 patients (63 M, 80 F; median age 64 years, range 11-87) with differentiated thyroid carcinoma (DTC). RESULTS: Radio-active iodine (RAI) treatment was performed in 131 patients (91.6%), surgical approach and/or external radiotherapy in 68 patients (47.6%), and anti-resorptive bone-active drugs in 32 patients (22.4%; in 31 zoledronate and in one denosumab). At the start of treatment, 24 patients (75.0%) receiving anti-resorptive bone-active drugs had at least one clinical skeletal-related event (SRE) (p < 0.001). One or more clinical SREs (pathological fractures and/or malignant hypercalcemia and/or spinal cord compression) developed in 53 patients (37.1%). Development of SREs was significantly associated with metachronous BM (hazard ratio (HR) 2.04; p = 0.04), localization of BM to cervical spine (HR 3.89; p = 0.01), and lack of avid RAI uptake (HR 2.66; p = 0.02). Thirty-nine patients (27.3%) died in correlation with development of SREs (HR 6.97; p = 0.006) and localization of BM to the hip (HR 3.86; p = 0.02). Moreover, overall mortality was significantly decreased by RAI therapy (HR 0.10; p = 0.02), whereas no significant effects were induced by bone-active drugs (p = 0.36), external radiotherapy (p = 0.54), and surgery (p = 0.43) of BM. CONCLUSIONS: SREs are very frequent in BM from DTC and they impact patient survival. In the real life, the use of bone-active drugs is currently limited to zoledronate in patients with pre-existing SREs. In this clinical setting, RAI therapy, but not zoledronate, decreased mortality.
PURPOSE AND PATIENTS: The M.O.S.CA.TI. (Metastases of the Skeleton from CArcinoma of the ThyroId) is a multicenter, retrospective study investigating the real-life outcome and management of bone metastases (BM) in 143 patients (63 M, 80 F; median age 64 years, range 11-87) with differentiated thyroid carcinoma (DTC). RESULTS: Radio-active iodine (RAI) treatment was performed in 131 patients (91.6%), surgical approach and/or external radiotherapy in 68 patients (47.6%), and anti-resorptive bone-active drugs in 32 patients (22.4%; in 31 zoledronate and in one denosumab). At the start of treatment, 24 patients (75.0%) receiving anti-resorptive bone-active drugs had at least one clinical skeletal-related event (SRE) (p < 0.001). One or more clinical SREs (pathological fractures and/or malignant hypercalcemia and/or spinal cord compression) developed in 53 patients (37.1%). Development of SREs was significantly associated with metachronous BM (hazard ratio (HR) 2.04; p = 0.04), localization of BM to cervical spine (HR 3.89; p = 0.01), and lack of avid RAI uptake (HR 2.66; p = 0.02). Thirty-nine patients (27.3%) died in correlation with development of SREs (HR 6.97; p = 0.006) and localization of BM to the hip (HR 3.86; p = 0.02). Moreover, overall mortality was significantly decreased by RAI therapy (HR 0.10; p = 0.02), whereas no significant effects were induced by bone-active drugs (p = 0.36), external radiotherapy (p = 0.54), and surgery (p = 0.43) of BM. CONCLUSIONS: SREs are very frequent in BM from DTC and they impact patient survival. In the real life, the use of bone-active drugs is currently limited to zoledronate in patients with pre-existing SREs. In this clinical setting, RAI therapy, but not zoledronate, decreased mortality.
Entities:
Keywords:
Bone metastases; Denosumab-radioiodine; Thyroid carcinoma; Zoledronate
Authors: Yun Mi Choi; Won Gu Kim; Hyemi Kwon; Min Ji Jeon; Jong Jin Lee; Jin-Sook Ryu; Eun-Gyoung Hong; Tae Yong Kim; Young Kee Shong; Won Bae Kim Journal: Eur J Endocrinol Date: 2016-06-07 Impact factor: 6.664
Authors: Y Mizukami; T Michigishi; A Nonomura; T Hashimoto; S Terahata; M Noguchi; K Hisada; F Matsubara Journal: Hum Pathol Date: 1990-03 Impact factor: 3.466
Authors: G Mazziotti; C Dordoni; M Doga; F Galderisi; M Venturini; P Calzavara-Pinton; R Maroldi; A Giustina; M Colombi Journal: Bone Date: 2015-12-18 Impact factor: 4.398
Authors: G Vitale; F Fonderico; A Martignetti; M Caraglia; A Ciccarelli; V Nuzzo; A Abbruzzese; G Lupoli Journal: Br J Cancer Date: 2001-06-15 Impact factor: 7.640
Authors: M Cellini; M Rotondi; M L Tanda; E Piantanida; L Chiovato; P Beck-Peccoz; Andrea Lania; G Mazziotti Journal: J Endocrinol Invest Date: 2020-07-21 Impact factor: 4.256
Authors: Arnaud Jannin; Livia Lamartina; Coralie Moutarde; Mehdi Djennaoui; George Lion; Benjamin Chevalier; Marie Christine Vantyghem; Frédéric Deschamps; Julien Hadoux; Eric Baudin; Martin Schlumberger; Sophie Leboulleux; Christine Do Cao Journal: Eur J Nucl Med Mol Imaging Date: 2022-02-12 Impact factor: 10.057
Authors: Salvatore Grisanti; Susanna Bianchi; Laura D Locati; Luca Triggiani; Stefania Vecchio; Alberto Bonetta; Cristiana Bergamini; Pierfranco Conte; Mario Airoldi; Marco Merlano; Paolo Carlini; Toni Ibrahim; Ciro Rossetto; Salvatore Alfieri; Paolo Pronzato; Sandro Tonoli; Roberto Maroldi; Piero Nicolai; Carlo Resteghini; Stefano M Magrini; Alfredo Berruti Journal: PLoS One Date: 2019-03-20 Impact factor: 3.240
Authors: A Nervo; A Ragni; F Retta; M Gallo; A Piovesan; V Liberini; M Gatti; U Ricardi; D Deandreis; E Arvat Journal: J Endocrinol Invest Date: 2020-08-03 Impact factor: 4.256